SWFI First Read, February 1, 2016

Kessler Topaz Meltzer & Check Filed Class Action Against Esperion Therapeutics

Radnor-based law firm Kessler Topaz Meltzer & Check, LLP filed a shareholder class action lawsuit against Esperion Therapeutics, Inc., a listed pharmaceutical company that focuses on developing and commercializing oral low-density lipoprotein cholesterol lowering therapies for patients with hypercholesterolemia. The class action alleges the company made false and/or misleading statements to investors, and failed to disclose material adverse facts during the class period between August 18, 2015 to September 28, 2015.

BloomReach Raises Series D Round

[ Content protected for Sovereign Wealth Fund Institute Standard subscribers only. Please subscribe to view content. ]

Contact the writer or creator of this article or page.
Questions or comments: support(at)swfinstitute(dot)org
Follow on Twitter at @swfinstitute and @sovereignfunds
Learn, Attend and Network: Institutional Investor Events and Summits
Go Back: HOME: Sovereign Wealth Fund Institute
institutional investor investment mandates